ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells

5-FU-based combinatory chemotherapeutic regimens have been routinely used for many years for the treatment of breast cancer patients. Recurrence and chemotherapeutic drug resistance are two of the most prominent factors that underpin the high mortality rates associated with most breast cancers (BC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuedong, Wang, Yueping, Gu, Juan, Zhou, Daoping, He, Zhimin, Wang, Xinhui, Ferrone, Soldano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575004/
https://www.ncbi.nlm.nih.gov/pubmed/28852196
http://dx.doi.org/10.1038/s41598-017-10468-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575004/
https://www.ncbi.nlm.nih.gov/pubmed/28852196
http://dx.doi.org/10.1038/s41598-017-10468-x

Ejemplares similares